PDL BioPharma Announces Fourth Quarter and Full Year 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall St slips as Middle East escalations lifts oil; Trump-Xi talks in focus
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Plug Power COO resigns to join another company
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Wall Street ends down as oil prices, Treasury yields rise
PDL BioPharma (PDLI) Tops Q4 EPS by 7c
February 22, 2016 4:04 PM ESTPDL BioPharma (NASDAQ: PDLI) reported Q4 EPS of $0.61, $0.07 better than the analyst estimate of $0.54. Revenue for the quarter came in at $178.1 million versus the consensus estimate of $149.2 million.
For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.
... More